🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study will evaluate the efficacy and safety of intravenous RC48-ADC co...
Status
Recruiting
Location
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Start Date
2022-11-23
Trial ID
NCT05917158
Treatments Being Tested
The purpose of this study is to evaluate the efficacy and safety of Disitam...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center
Start Date
2023-11-28
Trial ID
NCT06178159
Treatments Being Tested
This is an open-label, single-arm, Phase Ib/II investigator-initiated trial...
Status
Unknown
Location
Beijing Cancer Hospital
Start Date
2020-02-15
Trial ID
NCT04264936
Treatments Being Tested
This is a Phase II/III, randomized, multicenter, open-label clinical trial ...
Status
Active Not Recruiting
Location
Beijing Cancer Hospital
Start Date
2023-08-04
Trial ID
NCT05980481
The goal of this clinical trial is to learn if Disitamab Vedotin combined w...
Status
Recruiting
Location
Fujian Medical University Union Hospital
Start Date
2025-01
Trial ID
NCT06791070
Treatments Being Tested
This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study de...
Status
Recruiting
Location
Cancer Hospital Chinese Academy of Medical Sciences
Start Date
2022-06-14
Trial ID
NCT05302284
Treatments Being Tested
This is a prospective, open, single-center clinical study of RC48 combined ...
Status
Unknown
Location
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Start Date
2023-08-01
Trial ID
NCT05979740
Treatments Being Tested
This study will evaluate the efficacy and safety of intravenous RC48-ADC co...
Status
Unknown
Location
Beijing Cancer Hospital
Start Date
2022-05-26
Trial ID
NCT05297552
This study aims to evaluate the efficacy of disitamab vedotin combined with...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2025-08-30
Trial ID
NCT07151560
Treatments Being Tested
This study will evaluate the efficacy, safety and tolerability of RC48-ADC ...
Status
Withdrawn
Location
Binghe Xu
Start Date
2024-12-20
Trial ID
NCT06105008
Treatments Being Tested